News

August 13, 2018August 13, 2018

FDA Grants Fast Track Status to Castle Creek’s CCP-020 for Treatment of EBS

News

Castle Creek Pharmaceuticals‘ investigational treatment CCP-020 (diacerein 1% ointment) was granted Fast Track designation by the U.S. Food and Drug Administration to treat a type of epidermolysis bullosa (EB) called EB ... Read more

August 8, 2018August 8, 2018

Joint Venture Plans to Advance Potential EB Therapy RGN-137 into Phase 3 Trial

News

RGN-137, an experimental therapy for wound healing in epidermolysis bullosa (EB), is expected to advance into a Phase 3 trial, backed by a joint venture created by RegeneRx licensee GtreeBNT and YuYang DNU. ... Read more

August 6, 2018August 6, 2018

Amryt’s AP101 Granted Rare Pediatric Disease Designation for EB

News

Amryt Pharma’s investigational therapy AP101, designed to reduce the time it takes for skin wounds to close, was granted Rare Pediatric Disease designation by the U.S. Food and Drug ... Read more

August 1, 2018August 1, 2018

Blocking Inflammation-linked PI3K-Delta Molecule Could Lead to EBA Therapy, Mouse Study Suggests

News

Treatment targeting a specific molecule involved in inflammation — called PI3K-delta — eased skin lesions and prevented blistering in mouse models of epidermolysis bullosa acquisita (EBA), according to a ... Read more

July 30, 2018July 30, 2018

Antibiotic Gentamicin May Benefit About 80% of Herlitz JEB Patients, Study Says

News

The commonly used antibiotic gentamicin (brand name Garamycin) can reverse the effects of about 80% of genetic mutations affecting the LAMB3 gene that cause Herlitz junctional epidermolysis bullosa (H-JEB), according to researchers. ... Read more

July 25, 2018July 25, 2018

Cord Blood Platelet Gel Holds Potential to Treat Epidermolysis Bullosa, Study Shows

News

A gel made from platelets — tiny blood cells involved in blood clotting — collected from umbilical cord blood showed positive results for the topical treatment of patients with ... Read more

July 20, 2018July 20, 2018

Debra’s Family-oriented EB Care Conference Kicks Off Sunday in Arizona

News

The 2018 Debra Care Conference — a U.S. gathering of epidermolysis bullosa (EB) patients, families, disease advocates, and experts — gets underway this Sunday in suburban Phoenix. The biennial event, ... Read more

July 16, 2018July 16, 2018

Higher Levels of Granzyme B Play Key Role in EBA, Other Skin Blistering Diseases, Study Suggests

News

An enzyme called granzyme B (GzmB) may be a key mediator of blistering in patients with epidermolysis bullosa acquisita (EBA) and other autoimmune skin disorders, according to a Canadian ... Read more

July 11, 2018July 11, 2018

Case Report Highlights Rare EBA Diagnosis in 21-Year-Old Patient

News

A case report shows that epidermolysis bullosa acquisita (EBA), a rare form of epidermolysis bullosa that usually occurs in adulthood, can appear at earlier ages, even during adolescence. The study ... Read more

July 9, 2018July 9, 2018

Phase 1/2 Trial of DEB Therapy Candidate QR-313 Now Enrolling Patients, ProQR Announces

News

A Phase 1/2 clinical trial assessing investigational QR-313 as a treatment for dystrophic epidermolysis bullosa (DEB) has begun and is now enrolling participants, ProQR Therapeutics recently announced. The randomized, double-blind, placebo-controlled WINGS trial is ... Read more

Pin It on Pinterest